# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number k192299   
B Applicant Lin-Zhi International, Inc.   
C Proprietary and Established Names LZI Cotinine II Enzyme Immunoassay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>MKU</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.3220 -Carbon MonoxideTest System</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission: New Device   
B Measurand: Cotinine   
C Type of Test: Immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below

# B Indication(s) for Use:

The LZI Cotinine II Enzyme Immunoassay is intended for the qualitative and semi-quantitative determination of cotinine in human urine at the cutoff value of $2 0 0 ~ \mathrm { { n g / m L } }$ when calibrated against cotinine. The assay is intended as an aid in the detection of cotinine after use or exposure to tobacco products. The assay is designed for prescription use with a number of automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas or liquid chromatography/mass spectrometry (GC/MS or LC/MS) or (2) permitting laboratories to establish quality control procedures.

The assay provides only a preliminary analytical result. A more specific alternative chemical method (e.g., gas or liquid chromatograpy and mass spectrometry) must be used in order to obtain a confirmed analytical result. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

# C Special Conditions for Use Statement(s):

Prescription use only

# D Special Instrument Requirements:

Validation studies were conducted using the AU480 Chemistry Analyzer.

# IV Device/System Characteristics:

# A Device Description:

The LZI Cotinine Enzyme Immunoassay is a homogeneous enzyme immunoassay with ready-to use liquid reagents. The LZI Cotinine Enzyme Immunoassay is a kit comprised of two reagents, an R1 and R2, which are bottled separately but sold together within the kit. The R1 solution contains mouse monoclonal anti-cotinine antibody, glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide (NAD), stabilizers, and sodium azide $( 0 . 0 9 \% )$ as a preservative. The R2 solution contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with cotinine in buffer with sodium azide $( 0 . 0 9 \% )$ as a preservative.

# B Principle of Operation:

The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, cotininelabeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. On the other hand, when free drug is present in the sample, antibody would bind to free drug; the unbound cotinine-labeled G6PDH then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at $3 4 0 \mathrm { n m }$ .

# V Substantial Equivalence Information:

A Predicate Device Name(s): Niccheck I   
B Predicate 510(k) Number(s): k963733

C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>k192299</td><td rowspan=1 colspan=1>k963733</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>LZI Cotinine II EnzymeImmunoassay</td><td rowspan=1 colspan=1>NicCheckI</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Cotinine</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>200 ng/mL</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Intended Use/IndicationsFor Use</td><td rowspan=1 colspan=1>For the qualitative and semi-quantitative determination ofcotinine in human urine at thecutoff value of 200 ng/mLwhen calibrated againstcotinine. The assay is intendedas an aid in the detection ofcotinine after use or exposureto tobacco products.</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Differences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8°C until expiration date</td><td rowspan=1 colspan=1>2-8°C until 2 years from dateof manufacture. Test stripsare susceptible to conditionsof high humidity, the canistermust be kept tightly closedafter removal of the requirednumber of strips.</td></tr></table>

CLSI EP05-A3, Evaluation of Precision of Quantitative Measurement Procedures

VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

Cotinine samples (cotinine spiked negative urine pools) were run in replicates of 2, two runs per day (one in the morning and one in the afternoon) for 22 days on one AU480 automatic clinical analyzer for a total of 88 runs, in both qualitative and semi-quantitative modes. One single lot of reagents and calibrators and controls were used. Cotinine was spiked into samples at the concentrations shown in the tables below, and all sample cotinine concentrations were confirmed by LC/MS.

# Semi-Quantitative Positive/Negative Results:

<table><tr><td rowspan=1 colspan=2>200 ng/mL CutoffResult:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>CotinineConcentration</td><td rowspan=1 colspan=1>% ofCutoff</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>EIAResult</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>EIAResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>0.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>50 ng/mL</td><td rowspan=1 colspan=1>25.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>100 ng/mL</td><td rowspan=1 colspan=1>50.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>75.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>200 ng/mL</td><td rowspan=1 colspan=1>100.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>14 Neg/8TPos</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>55 Neg/33TPoss</td></tr><tr><td rowspan=1 colspan=1>250 ng/mL</td><td rowspan=1 colspan=1>125.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>150.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>350 ng/mL</td><td rowspan=1 colspan=1>175.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>400 ng/mL</td><td rowspan=1 colspan=1>200.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

Qualitative Positive/Negative Results:   

<table><tr><td rowspan=1 colspan=3>200 ng/mL CutoffResult:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=2>CotinineConcentration</td><td rowspan=1 colspan=1>% ofCutoff</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>EIAResult</td><td rowspan=1 colspan=1># ofDetermination</td><td rowspan=1 colspan=1>EIAResult</td></tr><tr><td rowspan=1 colspan=2>0 ng/mL</td><td rowspan=1 colspan=1>0.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=2>50 ng/mL</td><td rowspan=1 colspan=1>25.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=2>100 ng/mL</td><td rowspan=1 colspan=1>50.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=2>150 ng/mL</td><td rowspan=1 colspan=1>75.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=2>200 ng/mL</td><td rowspan=1 colspan=1>100.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>10 Neg/12Po</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>51 Neg/37Pos</td></tr><tr><td rowspan=1 colspan=1>250 ng/mL</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>125.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>150.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>350 ng/mL</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>175.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>400 ng/mL</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>200.0 %</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

# 2. Linearity:

A recovery/linearity study was performed by spiking cotinine into a pool of negative urine to create a $1 0 0 0 ~ \mathrm { { n g / m L } }$ high concentration. The high concentration was then diluted to reach the final concentrations listed in the table below. Each sample was run in 10 replicates on the AU480 automated clinical analyzer in semi-quantitative mode with a calibration curve established with the five Cotinine calibrators (0, 100, 200, 400, and $1 0 0 0 ~ \mathrm { { n g / m L } ) }$ . Recovery values (expected value divided by average observed value) were calculated and are presented in the table below.

<table><tr><td rowspan=1 colspan=1>TargetConcentration(ng/mL)</td><td rowspan=1 colspan=1>Determined(ng/mL)</td><td rowspan=1 colspan=2>%Recovery</td></tr><tr><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>978.9</td><td rowspan=1 colspan=2>97.9%</td></tr><tr><td rowspan=1 colspan=1>900</td><td rowspan=1 colspan=1>919.6</td><td rowspan=1 colspan=2>102.2%</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>851.7</td><td rowspan=1 colspan=2>106.5%</td></tr><tr><td rowspan=1 colspan=1>700</td><td rowspan=1 colspan=1>766.0</td><td rowspan=1 colspan=2>109.4%</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>664.8</td><td rowspan=1 colspan=2>110.8%</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>539.1</td><td rowspan=1 colspan=2>107.8%</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>395.0</td><td rowspan=1 colspan=2>98.8%</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>302.4</td><td rowspan=1 colspan=2>100.8%</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>199.9</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>109.0</td><td rowspan=1 colspan=2>109.0%</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>33.5</td><td rowspan=1 colspan=2>167.5%</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19.3</td><td rowspan=1 colspan=2>N/A</td></tr></table>

# 3. Analytical Specificity/Interference:

The compounds listed below were spiked into urine to the desired concentrations. These solutions were then split into three portions; one without cotinine, and the remaining two that were further spiked with cotinine standards obtained from Cerilliant to a final cotinine concentration of $1 5 0 ~ \mathrm { n g / m L }$ or $2 5 0 ~ \mathrm { { n g / m L } }$ (as negative or positive controls, $\pm 2 5 \%$ Cutoff Concentration, respectively). Samples were then evaluated against the assay’s calibration curve in both qualitative and semi-quantitative modes, and the results are as shown below (results were identical for both qualitative and semi-quantitative modes). Results indicated that there is interference from boric acid at $1 \% \mathrm { w / v }$ and citric acid. No other compounds showed interference concentrations at the concentrations tested. Data collected on the AU480 automated clinical analyzer is summarized in the following table:

Endogenous Compounds Interference   

<table><tr><td colspan="1" rowspan="2">Endogenous Substance</td><td colspan="1" rowspan="2">ConcentrationTested(ng/mL)</td><td colspan="3" rowspan="1">Spiked Cotinine Concentration</td></tr><tr><td colspan="1" rowspan="1">0 ng/mL</td><td colspan="1" rowspan="1">150 ng/mLControl</td><td colspan="1" rowspan="1">250 ng/mLControl</td></tr><tr><td colspan="1" rowspan="1">Acetone</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">1500</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Boric Acid</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Calcium Chloride (CaCl2)</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Citric Acid (pH 3)</td><td colspan="1" rowspan="1">800</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ethanol</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Galactose</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">γ-Globulin</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1">3000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">β-hydroxybutyric Acid</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">HAS</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Oxalic Acid</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Potassium Chloride</td><td colspan="1" rowspan="1">6000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Riboflavin</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">6000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Sodium Azide</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Sodium Chloride</td><td colspan="1" rowspan="1">6000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Sodium Fluoride</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Sodium Phosphate</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Endogenous Substance</td><td rowspan=2 colspan=1>ConcentrationTested(ng/mL)</td><td rowspan=1 colspan=3>Spiked Cotinine Concentration</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>100 ng/mLControl</td><td rowspan=1 colspan=1>300 ng/mLControl</td></tr><tr><td rowspan=1 colspan=1>Boric Acid</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Citric Acid (pH 3)</td><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr></table>

# pH Interference Study

Drug free urine and urine spiked with cotinine to the final cotinine concentration of either $1 5 0 ~ \mathrm { { n g / m L } }$ or $2 5 0 ~ \mathrm { { n g / m L } }$ (as negative or positive controls, $\pm 2 5 \%$ cutoff concentration, respectively) were adjusted to the $\mathsf { p H }$ levels reported in the table below and tested by the assay. The $\mathsf { p H }$ adjusted solutions were evaluated against the cutoff calibrator. No major interference between $\mathrm { p H } 3$ to pH 11. Results are summarized in the table below.

<table><tr><td rowspan=2 colspan=1>pH</td><td rowspan=1 colspan=3>Spiked Cotinine Concentration</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>150 ng/mLControl</td><td rowspan=1 colspan=1>250 ng/mLControl</td></tr><tr><td rowspan=1 colspan=1>pH 3</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 4</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 5</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 6</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 7</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 8</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 9</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 11</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr></table>

# Specific Gravity Interference Study

Samples ranging in specific gravity from 1.005 to 1.028 were split into three portions each and either left un-spiked or further spiked to a final cotinine concentration of either $1 5 0 ~ \mathrm { n g / m L }$ or $2 5 0 ~ \mathrm { { n g / m L } }$ (as negative or positive controls, $\pm 2 5 \%$ cutoff concentration, respectively). These samples were then evaluated in qualitative mode. No interference was observed at any specific gravity.

# Cross-Reactivity Study

The cross-reactivity of various potentially interfering drugs were tested by spiking various concentrations of each substance listed in the table below into drug free urine and then evaluating the sample against the assay. The results are summarized in the tables below.

# Cotinine

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>TargetConcentration(ng/mL)</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>(-)-Cotinine</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100.00%</td></tr></table>

# Cotinine Metabolites

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>TargetConcentration(ng/mL)</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>(+)-Anabasine</td><td rowspan=1 colspan=1>250,000</td><td rowspan=1 colspan=1>0.08%</td></tr><tr><td rowspan=1 colspan=1>S(-)-Nicotine</td><td rowspan=1 colspan=1>25,000</td><td rowspan=1 colspan=1>0.80%</td></tr><tr><td rowspan=1 colspan=1>Nicotinic Acid (Niacin)</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.20%</td></tr><tr><td rowspan=1 colspan=1>(-) Norcotinine</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>20.00%</td></tr><tr><td rowspan=1 colspan=1>(+) Norcotinine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.20%</td></tr><tr><td rowspan=1 colspan=1>(R, S)-Norcotinine</td><td rowspan=1 colspan=1>850</td><td rowspan=1 colspan=1>23.53%</td></tr><tr><td rowspan=1 colspan=1>(±)-Nornicotine</td><td rowspan=1 colspan=1>250,000</td><td rowspan=1 colspan=1>0.08%</td></tr><tr><td rowspan=1 colspan=1>trans-3&#x27;-hydroxycotinine</td><td rowspan=1 colspan=1>10,000</td><td rowspan=1 colspan=1>2.00%</td></tr></table>

Cross-reactivity of various potentially interfering drugs were tested by spiking $1 0 0 , 0 0 0 \mathrm { n g / m L }$ (or as listed in the table below) of each substance into drug free urine. These solutions were then split into three portions; one without Cotinine, and two that were further spiked with Cotinine to a final Cotinine concentration of $1 5 0 ~ \mathrm { n g / m L }$ or $2 5 0 ~ \mathrm { { n g / m L } }$ (as negative or positive controls, $\pm 2 5$ $\%$ Cutoff Concentration, respectively). Samples were then evaluated with the assay. The results are as shown below.

Structurally Unrelated Pharmacological Compounds   

<table><tr><td colspan="1" rowspan="2">Cross-reactant</td><td colspan="1" rowspan="2">Spiked [](ng/mL)</td><td colspan="3" rowspan="1">Spiked Cotinine Concentration</td></tr><tr><td colspan="1" rowspan="1">0 ng/mL</td><td colspan="1" rowspan="1">150 ng/mLControl</td><td colspan="1" rowspan="1">250 ng/mLControl</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">6-Acetylmorphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Amlodipine Besylate</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Azelastine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">d-Amphetamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Atorvastatin</td><td colspan="1" rowspan="1">20,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Brompheniramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">15,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Bupropion</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Carbinoaxmine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Cetirizine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Chlorpheniramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Clemastine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Cyproheptadine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Desloratadine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Dexchlorpheniramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Duloxetine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Emedastine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fentanyl (citrate)</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fexofenadine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fluoxetine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Fluphenazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Gabapentin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Hydroxyzine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Lisinopril</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Levocabastine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Losartan</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr></table>

Structurally Unrelated Pharmacological Compounds, continued   

<table><tr><td colspan="1" rowspan="2">Cross-reactant</td><td colspan="1" rowspan="2">Spiked []ng/mL)</td><td colspan="3" rowspan="1">Spiked Cotinine Concentration</td></tr><tr><td colspan="1" rowspan="1">0 ng/mL</td><td colspan="1" rowspan="1">150 ng/mLControl</td><td colspan="1" rowspan="1">250 ng/mLControl</td></tr><tr><td colspan="1" rowspan="1">Loratidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">MDA (3,4-methylenedioxyamphetamine)</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">MDEA</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">MDMA (3,4-methylenedioxymethamphetamine)</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="2">Cross-reactant</td><td colspan="1" rowspan="2">Spiked [](ng/mL)</td><td colspan="3" rowspan="1">Spiked Cotinine Concentration</td></tr><tr><td colspan="1" rowspan="1">0 ng/mL</td><td colspan="1" rowspan="1">150 ng/mLControl</td><td colspan="1" rowspan="1">250 ng/mLControl</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Metformin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Methapyrilene</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Metoprolol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">d-Methamphetamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Nortriptyline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Omeprazole</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Promethazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">(1S,2S)-(+)Pseudoephedrine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Quetiapine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Salbutamol(Albuterol)</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Sertraline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Terfenadine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">THC-COOH(11-Nor-Delta-9-THC-9-carboxylicacid)</td><td colspan="1" rowspan="1">1,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">l-Thyroxine</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Tramadol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Triprolidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr><tr><td colspan="1" rowspan="1">Zolpidem</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">ND</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Pos</td></tr></table>

4. Assay Reportable Range: Not Applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

The device is traceable to certified Cerilliant Cotinine, verified by HPLC and GC/MS. Purity determination and gravimetric preparation using balances calibrated with NIST traceable weights ensured the accuracy of the stock standard solution.

6. Detection Limit:

See section VII.A.1 above

See section VII.A.1 above

# B Comparison Studies:

# 1. Method Comparison with Predicate Device

A total of one-hundred and four (104) unaltered clinical samples were tested with the LZI Cotinine II Enzyme Immunoassay on the AU480 automated clinical analyzer. Samples were evaluated against the assay’s calibration curve in both qualitative and semi-quantitative modes. All samples were tested in singlet. All samples were confirmed with LC/MS for cotinine concentrations, and the accuracy of the assay to LC/MS is provided in the table below.

Semi-Quantitative Results   

<table><tr><td rowspan=1 colspan=1>CandidateDeviceResults200ng/mLCutoff</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>&lt; 50 % ofthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50 %below thecutoff and thecutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>HighPositive(Greater than50 % abovethe cutoffconcentration)</td><td rowspan=1 colspan=1>%Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>96.4 %</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>1**</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98.7 %</td></tr></table>

<table><tr><td>Sample #</td><td>GC/MS Cotinine (ng/mL)</td><td>Pos/ Neg Result</td></tr><tr><td>57*</td><td>128.6</td><td>-</td></tr><tr><td>78**</td><td>204.2</td><td>+</td></tr></table>

Qualitative Results

<table><tr><td rowspan=1 colspan=1>CandidateDeviceResults200ng/mLCutoff</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>&lt; 50 % ofthe cutoffconcentrationby GC/MSanalysis</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50 %below thecutoff and thecutoffconcentration)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50% above thecutoffconcentration)</td><td rowspan=1 colspan=1>HighPositive(Greater than50 % abovethe cutoffconcentration)</td><td rowspan=1 colspan=1>%Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>96.4 %</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>1**</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98.7 %</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample #</td><td rowspan=1 colspan=1>GC/MSCotinine(ng/mL)</td><td rowspan=1 colspan=1>Pos/NegResult</td></tr><tr><td rowspan=1 colspan=1>57*</td><td rowspan=1 colspan=1>128.6</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>78**</td><td rowspan=1 colspan=1>204.2</td><td rowspan=1 colspan=1>+</td></tr></table>

2. Matrix Comparison: Not applicable.

C Clinical Studies: Not Applicable.   
D Clinical Cut-Off: See section VII.A.1. above   
E Expected Values/Reference Range: Not Applicable.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.